Pharmacological management of IPF

Respirology

Volumn 21, Issue 4, 2016, Pages 615-625

  Borie, Raphael ^a,b,c   Justet, Aurelien ^a,b,c   Beltramo, Guillaume ^a,b,c   Manali, Effrosyni D ^d   Pradère, Pauline ^a,b,c   Spagnolo, Paolo ^e   Crestani, Bruno ^a,b,c  

^a BICHAT HOSPITAL   (France)

^b Service de Pneumologie A Département hospitalo universitaire FIRE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e UNIVERSITY OF PADOVA   (Italy)

Author keywords

cough; exacerbation; nintedanib; pirfenidone; pulmonary hypertension

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; ANTICOAGULANT AGENT; AZATHIOPRINE; BOSENTAN; CARLUMAB; COLLAGEN TYPE 5; COTRIMOXAZOLE; ETANERCEPT; EVEROLIMUS; FRESOLIMUMAB; HEPARIN; IMATINIB; INTERFERON; LEBRIKIZUMAB; MACITENTAN; NINTEDANIB; OMIPALISIB; PAMREVLUMAB; PIRFENIDONE; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; SILDENAFIL; SIMTUZUMAB; TANZISERTIB; TRALOKINUMAB; UNINDEXED DRUG; WARFARIN; IMMUNOSUPPRESSIVE AGENT; INDOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANTICOAGULATION; BODY WEIGHT DISORDER; DECREASED APPETITE; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPEPSIA; FATIGUE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INTERSTITIAL PNEUMONIA; MORTALITY; MULTICENTER STUDY (TOPIC); NAUSEA; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK REDUCTION; SYMPTOM; TREATMENT WITHDRAWAL; VOMITING; WEIGHT REDUCTION; DISEASE COURSE; DRUG EFFECTS; IDIOPATHIC PULMONARY FIBROSIS; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; TREATMENT OUTCOME;

DISEASE PROGRESSION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; INDOLES; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84963704138     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12778     Document Type: Review

References (83)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al., Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788-824.
2. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, et al., An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2015; 192: e3-19.
3. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, et al., Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebocontrolled trial. Lancet 2009; 374: 222-8.
4. King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, Valeyre D, Leconte I, Morganti A, Roux S, et al., BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 184: 92-9.
5. Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J, MUSIC Study Group. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur. Respir. J. 2013; 42: 1622-32.
6. Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Nathan SD, Wells AU, Collard HR, et al., Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann. Intern. Med. 2013; 158: 641-9.
7. Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, Anstrom KJ, Martinez FJ, IPFnet Investigators. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest 2013; 143: 1699-708.
8. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA, Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2012; 186: 88-95.
9. Idiopathic Pulmonary Fibrosis Clinical Research N, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ,. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012; 366: 1968-77.
10. Idiopathic Pulmonary Fibrosis Clinical Research N, Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G,. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2093-101.
11. Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, Thomeer M, Utz JP, Khandker RK, McDermott L, et al., Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2008; 178: 948-55.
12. Malouf MA, Hopkins P, Snell G, Glanville AR, Everolimus in IPF Study Investigators. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology 2011; 16: 776-83.
13. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR, Imatinib-IPF Study. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am. J. Respir. Crit. Care Med. 2010; 181: 604-10.
14. Molyneaux PL, Cox MJ, Willis-Owen SA, Mallia P, Russell KE, Russell AM, Murphy E, Johnston SL, Schwartz DA, Wells AU, et al., The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2014; 190: 906-13.
15. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, et al., High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2005; 353: 2229-42.
16. Oldham JM, Ma SF, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, Valenzi E, Witt L, Lee C, Vij R, et al., TOLLIP, MUC5B and the Response to N-Acetylcysteine Among Individuals with Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2015; 192: 1475-82.
17. Raghu G, Martinez FJ, Brown KK, Costabel U, Cottin V, Wells AU, Lancaster L, Gibson KF, Haddad T, Agarwal P, et al., CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. Eur. Respir. J. 2015; 46: 1740-50.
18. Wilkes DS, Chew T, Flaherty KR, Frye S, Gibson KF, Kaminski N, Klemsz MJ, Lange W, Noth I, Rothhaar K,. Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. Eur. Respir. J. 2015; 45: 1393-402.
19. Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, Sasaki H,. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-82.
20. Crooks MG, Hart SP,. Coagulation and anticoagulation in idiopathic pulmonary fibrosis. Eur. Respir. Rev. 2015; 24: 392-9.
21. Wilson EC, Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Twentyman OP, Wilson AM,. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial. Pharmacoeconomics 2014; 32: 87-99.
22. Schaefer CJ, Ruhrmund DW, Pan L, Seiwert SD, Kossen K,. Antifibrotic activities of pirfenidone in animal models. Eur. Respir. Rev. 2011; 20: 85-97.
23. Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C,. Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur. J. Pharm. Sci. 2014; 58: 13-9.
24. Raghu G, Johnson WC, Lockhart D, Mageto Y,. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med. 1999; 159: 1061-9.
25. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al., Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2005; 171: 1040-7.
26. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, et al., Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 2010; 35: 821-9.
27. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, et al., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-9.
28. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083-92.
29. Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE Jr, Lancaster LH, Nathan SD, et al., Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Chest 2015; 148: 196-201.
30. Seto Y, Inoue R, Kato M, Yamada S, Onoue S,. Photosafety assessments on pirfenidone: photochemical, photobiological, and pharmacokinetic characterization. J. Photochem. Photobiol. B 2013; 120: 44-51.
31. Arai T, Inoue Y, Sasaki Y, Tachibana K, Nakao K, Sugimoto C, Okuma T, Akira M, Kitaichi M, Hayashi S,. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig. 2014; 52: 136-43.
32. Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS,. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm. Pharmacol. Ther. 2009; 22: 279-85.
33. Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, Noble PW, Sahn SA, du Bois RM,. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014; 19: 740-7.
34. Costabel U, Bendstrup E, Cottin V, Dewint P, Egan JJ, Ferguson J, Groves R, Hellstrom PM, Kreuter M, Maher TM, et al., Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv. Ther. 2014; 31: 375-91.
35. Costabel U, Albera C, Bradford WZ, Hormel P, King TE Jr, Noble PW, Sahn SA, Valeyre D, Du Bois RM,. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2014; 31: 198-205.
36. Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A, Luppi F, Saltini C, Agostini C, Bargagli E, et al., Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study. Respir. Med. 2015; 109: 904-13.
37. Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D, Andreas S, Claussen M, Grohe C, Wilkens H, et al., Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur. Respir. J. 2015; 46: 186-96.
38. Loeh B, Drakopanagiotakis F, Bandelli GP, von der Beck D, Tello S, Cordani E, Rizza E, Barrocu L, Markart P, Seeger W, et al., Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2015; 191: 110-3.
39. Ogura T, Azuma A, Inoue Y, Taniguchi H, Chida K, Bando M, Niimi Y, Kakutani S, Suga M, Sugiyama Y, et al., All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respir Investig. 2015; 53: 232-41.
40. Ogura T, Taniguchi H, Azuma A, Inoue Y, Kondoh Y, Hasegawa Y, Bando M, Abe S, Mochizuki Y, Chida K, et al., Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J. 2015; 45: 1382-92.
41. Huang H, Dai HP, Kang J, Chen BY, Sun TY, Xu ZJ,. Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients. Medicine (Baltimore) 2015; 94: e1600.
42. Wijsenbeek MS, Grutters JC, Wuyts WA,. Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis. Adv. Ther. 2015; 32: 691-704.
43. Bando M, Sugiyama Y, Azuma A, Ebina M, Taniguchi H, Taguchi Y, Takahashi H, Homma S, Nukiwa T, Kudoh S,. A prospective survey of idiopathic interstitial pneumonias in a web registry in Japan. Respir Investig. 2015; 53: 51-9.
44. Sakamoto S, Muramatsu Y, Satoh K, Ishida F, Kikuchi N, Sano G, Sugino K, Isobe K, Takai Y, Homma S,. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Respirology 2015; 20: 445-52.
45. Alhamad EH,. Pirfenidone treatment in idiopathic pulmonary fibrosis: A Saudi experience. Ann. Thorac. Med. 2015; 10: 38-43.
46. Iwata T, Yoshida S, Nagato K, Nakajima T, Suzuki H, Tagawa T, Mizobuchi T, Ota S, Nakatani Y, Yoshino I,. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surg. Today 2015; 45: 1263-70.
47. Oltmanns U, Kahn N, Palmowski K, Trager A, Wenz H, Heussel CP, Schnabel PA, Puderbach M, Wiebel M, Ehlers-Tenenbaum S, et al., Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration 2014; 88: 199-207.
48. Chaudhuri N, Duck A, Frank R, Holme J, Leonard C,. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir. Med. 2014; 108: 224-6.
49. Sakamoto S, Itoh T, Muramatsu Y, Satoh K, Ishida F, Sugino K, Isobe K, Homma S,. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis. Intern. Med. 2013; 52: 2495-501.
50. Okuda R, Hagiwara E, Baba T, Kitamura H, Kato T, Ogura T,. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir. Med. 2013; 107: 1431-7.
51. Cottin V, Maher T,. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. Rev. 2015; 24: 58-64.
52. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, et al., BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008; 68: 4774-82.
53. Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE,. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur. Respir. J. 2007; 29: 976-85.
54. Hostettler KE, Zhong J, Papakonstantinou E, Karakiulakis G, Tamm M, Seidel P, Sun Q, Mandal J, Lardinois D, Lambers C, et al., Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir. Res. 2014; 15: 157.
55. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, et al., Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2011; 365: 1079-87.
56. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al., Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071-82.
57. Costabel U, Inoue Y, Richeldi L, Collard HR, Tschoepe I, Stowasser S, Azuma A,. Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis Across Pre-specified Subgroups in INPULSIS(R). Am. J. Respir. Crit. Care Med. 2016; 193: 178-85.
58. Corte T, Bonella F, Crestani B, Demedts MG, Richeldi L, Coeck C, Pelling K, Quaresma M, Lasky JA,. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir. Res. 2015; 16: 116.
59. Taguchi Y, Ebina M, Hashimoto S, Ogura T, Azuma A, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, et al., Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan. Respir Investig. 2015; 53: 279-87.
60. Loveman E, Copley VR, Scott DA, Colquitt JL, Clegg AJ, O'Reilly KM,. Comparing new treatments for idiopathic pulmonary fibrosis - a network meta-analysis. BMC Pulm. Med. 2015; 15: 37.
61. Milger K, Kneidinger N, Neurohr C, Reichenberger F, Behr J,. Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF. Eur. Respir. J. 2015; 46: 1217-21.
62. Karimi-Shah BA, Chowdhury BA,. Forced vital capacity in idiopathic pulmonary fibrosis-FDA review of pirfenidone and nintedanib. N. Engl. J. Med. 2015; 372: 1189-91.
63. Thabut G, Crestani B, Porcher R, Richeldi L,. Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough. Eur. Respir. J. 2015; 46: 607-14.
64. Crestani B, Chapron J, Wallaert B, Bergot E, Delaval P, Israel-Biet D, Lacronique J, Monnet I, Reynaud-Gaubert M, Tazi A, et al., Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study. Eur. Respir. J. 2012; 39: 772-5.
65. Wuyts WA, Antoniou KM, Borensztajn K, Costabel U, Cottin V, Crestani B, Grutters JC, Maher TM, Poletti V, Richeldi L, et al., Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir. Med. 2014; 2: 933-42.
66. Seeger W, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galie N, Ghio S, Gibbs S, et al., Pulmonary hypertension in chronic lung diseases. J. Am. Coll. Cardiol. 2013; 62: D109-16.
67. Raghu G, Nathan SD, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, Martinez FJ, Wells AU, Shao L, et al., Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. Eur. Respir. J. 2015; 46: 1370-7.
68. Corte TJ, Keir GJ, Dimopoulos K, Howard L, Corris PA, Parfitt L, Foley C, Yanez-Lopez M, Babalis D, Marino P, et al., Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2014; 190: 208-17.
69. Idiopathic Pulmonary Fibrosis Clinical Research N, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW,. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N. Engl. J. Med. 2010; 363: 620-8.
70. Hoeper MM, Halank M, Wilkens H, Gunther A, Weimann G, Gebert I, Leuchte HH, Behr J,. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur. Respir. J. 2013; 41: 853-60.
71. Harrison NK,. Cough, sarcoidosis and idiopathic pulmonary fibrosis: raw nerves and bad vibrations. Cough 2013; 9: 9.
72. Hope-Gill BD, Hilldrup S, Davies C, Newton RP, Harrison NK,. A study of the cough reflex in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2003; 168: 995-1002.
73. Ryerson CJ, Abbritti M, Ley B, Elicker BM, Jones KD, Collard HR,. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 2011; 16: 969-75.
74. Savarino E, Carbone R, Marabotto E, Furnari M, Sconfienza L, Ghio M, Zentilin P, Savarino V,. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur. Respir. J. 2013; 42: 1322-31.
75. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, Sillery JK, Pope CE 2nd, Pellegrini CA,. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur. Respir. J. 2006; 27: 136-42.
76. Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G, IPFnet Investigators. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013; 1: 369-76.
77. Kilduff CE, Counter MJ, Thomas GA, Harrison NK, Hope-Gill BD,. Effect of acid suppression therapy on gastroesophageal reflux and cough in idiopathic pulmonary fibrosis: an intervention study. Cough 2014; 10: 4.
78. Horton MR, Santopietro V, Mathew L, Horton KM, Polito AJ, Liu MC, Danoff SK, Lechtzin N,. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann. Intern. Med. 2012; 157: 398-406.
79. Morawiec E, Tillie-Leblond I, Pansini V, Salleron J, Remy-Jardin M, Wallaert B,. Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses. Eur. Respir. J. 2011; 38: 1487-9.
80. Donahoe M, Valentine VG, Chien N, Gibson KF, Raval JS, Saul M, Xue J, Zhang Y, Duncan SR,. Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis. PLoS One 2015; 10: e0127771.
81. Kataoka K, Taniguchi H, Kondoh Y, Nishiyama O, Kimura T, Matsuda T, Yokoyama T, Sakamoto K, Ando M,. Recombinant Human Thrombomodulin in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Chest 2015; 148: 436-43.
82. Ryerson CJ, Cottin V, Brown KK, Collard HR,. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur. Respir. J. 2015; 46: 512-20.
83. Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, Lederer DJ, Mulligan MJ, Patterson GA, Singer LG, et al., A consensus document for the selection of lung transplant candidates: 2014 - an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant. 2015; 34: 1-15.